The IVO-LUNG Study

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-10-01

Summary

This Phase II, open-label, single-arm study evaluates the efficacy and safety of one-year Ivonescimab consolidation therapy in patients with unresectable Stage III NSCLC who have not progressed after definitive chemoradiotherapy.

• Phase: PHASE2

Details

• Lead Sponsor: Sun Yat-sen University